Prescient Therapeutics Investor Briefing – 14 August
Prescient Therapeutics (ASX: PTX) Webcast Replay
Steven Yatomi-Clarke, CEO & MD of Prescient Therapeutics (ASX:PTX) provides an update on the company’s next-gen CAR-T asset enhanced cell therapy capabilities – maybe the most promising global frontier in the fight against cancer – as well as their other cancer therapy programs.
Recorded on 14 August 2020 at 11 am (AEST).
Join the next Prescient Therapeutics webcastFEATURE SPEAKERS
WARRICK LACE
Investor Relation Manager - Reach Markets
STEVEN YATOMI-CLARKE
Chief Executive Officer & Managing Director - Prescient Therapeutics
